Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Canal

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
Bulletin Du Cancer|August 1, 1997
[Inefficacy of exchange-transfusion in case of a methotrexate poisoning]S Bénézet, E Chatelut, H Bagheri, et al.
Journal of the American Society of Nephrology : JASN|December 16, 1998
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implicationsL Rostaing, E Chatelut, J L Payen, et al.
Nephron|January 1, 1994
Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiencyE Chatelut, L Rostaing, V Gualano, et al.
Cancer Chemotherapy and Pharmacology|January 27, 1998
Population pharmacokinetics of total and unbound etoposideL Nguyen, E Chatelut, C Chevreau, et al.
Clinical Pharmacology and Therapeutics|March 1, 1992
Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicitiesP Canal, J Robert, M Ramon, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2000
Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humansR Guimbaud, S Guichard, C Dusseau, et al.
European Journal of Clinical Pharmacology|January 29, 1999
Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide scheduleN Perdaems, J M Bachaud, P Rouzaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearanceM C Etienne, F Leger, X Pivot, et al.
Cancer Chemotherapy and Pharmacology|March 11, 1999
A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patientsB Tranchand, C Amsellem, E Chatelut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of CancerP Canal, C Gay, A Dezeuze, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
Bulletin Du Cancer|August 1, 1997
[Inefficacy of exchange-transfusion in case of a methotrexate poisoning]S Bénézet, E Chatelut, H Bagheri, et al.
Journal of the American Society of Nephrology : JASN|December 16, 1998
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implicationsL Rostaing, E Chatelut, J L Payen, et al.
Nephron|January 1, 1994
Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiencyE Chatelut, L Rostaing, V Gualano, et al.
Cancer Chemotherapy and Pharmacology|January 27, 1998
Population pharmacokinetics of total and unbound etoposideL Nguyen, E Chatelut, C Chevreau, et al.
Clinical Pharmacology and Therapeutics|March 1, 1992
Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicitiesP Canal, J Robert, M Ramon, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2000
Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humansR Guimbaud, S Guichard, C Dusseau, et al.
European Journal of Clinical Pharmacology|January 29, 1999
Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide scheduleN Perdaems, J M Bachaud, P Rouzaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearanceM C Etienne, F Leger, X Pivot, et al.
Cancer Chemotherapy and Pharmacology|March 11, 1999
A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patientsB Tranchand, C Amsellem, E Chatelut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of CancerP Canal, C Gay, A Dezeuze, et al.
Pageof 15